Benzinga | Dec 20, 2021 04:49AM EST

SVB Leerink Maintains Outperform on Biogen, Lowers Price Target to $325

SVB Leerink analyst Marc Goodman maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $450 to $325.